Search
ACR-16
go.drugbank.com/drugs/DB05371InvestigationalACR-16 is under investigation by NeuroSearch. ACR16 has been successfully investigated in a Phase II multi-centre, randomised and placebo-controlled trial in patients with Huntington’s disease as well as in three Phase Ib studies within ...
Cannabidivarin
go.drugbank.com/drugs/DB14050InvestigationalIt is one of over 100 cannabinoids identified from the Cannabis plant that can modulate the physiological activity of cannabis, or marijuana [A32584]. … their physiological effects through their binding to the cannabinoid-1 (CB1R) and cannabinoid-2 (CB2R) receptors, the investigational cannabinoids with anticonvulsant action mostly use mechanisms that do
Quercus acutissima whole
go.drugbank.com/drugs/DB14373InvestigationalIt is not an approved drug.
Mixtures: Dr. Forest Hand Sanitizer, Dr. Forest Hand SanitizerCeftobiprole
go.drugbank.com/drugs/DB04918ApprovedWithdrawnMedicinal Products for Human Use (CHMP) adopted a negative opinion of ceftobiprole medocaril in February 2010, recommending the refusal of its marketing authorization in the European Union primarily due
Trypan blue free acid
go.drugbank.com/drugs/DB09158ApprovedTrypan blue is a diazo dye used in ophthalmic cataract surgery to stain the anterior capsule in the presence of a mature cataract. This is done to aid in visualization before creating the continuous curvilinear capsulorhexis.
Edaravone
go.drugbank.com/drugs/DB12243ApprovedInvestigational[L44007] The oral suspension formulation of edaravone was approved by the FDA in May 2022 and by Health Canada in November 2022. … [L44007] It was later approved for the treatment of amyotrophic lateral sclerosis (ALS) in Japan and South Korea in 2015, followed by the FDA approval in May 2017 [L41810] and Health Canada approval in
Volixibat
go.drugbank.com/drugs/DB13914InvestigationalVolixibat, also known as SHP626 or LUM002, is an investigational drug that will potentially be used for the treatment of Non-Alcoholic Steatohepatitis (NASH). … According to Shire, the pharmaceutical manufacturer of Volixibat, it has been granted fast track status by the Food and Drug Administration due to promising initial results and a need for therapeutic treatments
Benidipine
go.drugbank.com/drugs/DB09231Investigational[A31948] It was originated in Japan by Kyowa Hakko, it is submitted for FDA approval and it is currently available in some Asian countries like India and Japan.[L1385, L1386]
DS-2325a
go.drugbank.com/drugs/DB18134InvestigationalDS-2325a is an inhibitor of kallikrein 5 under development for the treatment of Netherton Syndrome.
Rapacuronium
go.drugbank.com/drugs/DB04834ApprovedWithdrawnRapacuronium was withdrawn in 2001 in many countries due to risk of fatal bronchospasm.